Dow Surges 500 Points; Johnson & Johnson Lowers Guidance
U.S. stocks traded higher midway through trading, with the Dow Jones gaining around 500 points on Tuesday.
This Financial Services Stock Is Trading Higher By 50%, Here Are 40 Stocks Moving In Tuesday’s Mid-Day Session
Gainers
Applied Blockchain, Inc. (NASDAQ: APLD) jumped 50.1% to $1.5907 after the company reported a 200-megawatt five-year hosting contract with Marathon Digital Holdings and raised its Q4 revenue forecast.
The Daily Biotech Pulse: FDA Tentatively Approves Avadel’s Narcolepsy Drug, European Approval Broadens AstraZeneca’s Enhertu in Breast Cancer, Pharma Giants’ Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours:
Apellis Shares Climb As FDA Accepts Geographic Atrophy Candidate Submission Under Priority Review
The U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review designation for Apellis Pharmaceuticals’ (NASDAQ: APLS) New Drug Application (NDA) for the intravitreal pegcetacoplan.
The regulatory agency has assigned target action date of November 26, 2022.
The Daily Biotech Pulse: Precision BioSciences Inks Gene Editing Pact, Athira Pharma’s Alzheimer’s Candidate Fails, Enanta Sues Pfizer Over COVID-19 Antiviral
Here's a roundup of top developments in the biotech space over the last 24 hours:
The Daily Biotech Pulse: FDA Adcomm Backing For Novavax’s COVID-19 Shot, New Data On Moderna’s Omicron Vaccine, DBV Tech’s Encouraging Peanut Allergy Trial Data
Here's a roundup of top developments in the biotech space over the last 24 hours:
Apellis Pharmaceuticals Granted FDA Orphan Drug Designation for Pegcetacoplan for Treatment of Immune Complex-membranoproliferative Glomerulonephritis
https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=799620
Apellis Begins Paitent Dosing In Late-Stage Study Of Rare Kidney Disease Candidate
Apellis Pharmaceuticals (NASDAQ: APLS) has dosed first patient in the VALIANT Phase 3 clinical study of its drug candidate Pegcetacoplan for primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN) and C3 glomerulopathy (C3G), two rare and debilitating kidney diseases with similar underlyin
Apellis Announces Submission Of New Drug Application To FDA For Pegcetacoplan For Geographic Atrophy
WALTHAM, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), a global biopharmaceutical company and leader in complement, today announced that the company has submitted a New Drug